| __timestamp | Alnylam Pharmaceuticals, Inc. | Bausch Health Companies Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 50561000 | 8263500000 |
| Thursday, January 1, 2015 | 41097000 | 10498800000 |
| Friday, January 1, 2016 | 47159000 | 9674000000 |
| Sunday, January 1, 2017 | 89912000 | 8724000000 |
| Monday, January 1, 2018 | 74908000 | 8380000000 |
| Tuesday, January 1, 2019 | 219750000 | 8601000000 |
| Wednesday, January 1, 2020 | 492853000 | 8027000000 |
| Friday, January 1, 2021 | 844287000 | 8434000000 |
| Saturday, January 1, 2022 | 1037418000 | 8124000000 |
| Sunday, January 1, 2023 | 1828292000 | 8757000000 |
| Monday, January 1, 2024 | 2248243000 |
Cracking the code
In the dynamic world of pharmaceuticals, revenue performance is a key indicator of a company's market position and growth potential. Alnylam Pharmaceuticals, Inc. and Bausch Health Companies Inc. have shown contrasting revenue trajectories over the past decade. From 2014 to 2023, Alnylam's revenue skyrocketed by approximately 3,500%, starting from a modest $50 million to an impressive $1.8 billion. This growth reflects Alnylam's successful innovation and market expansion strategies.
Conversely, Bausch Health's revenue has remained relatively stable, fluctuating around the $8 billion mark. Despite a slight dip in 2020, Bausch Health has maintained a strong revenue base, showcasing its resilience in a competitive market. This comparison highlights Alnylam's rapid ascent in the pharmaceutical industry, while Bausch Health continues to leverage its established market presence.
Annual Revenue Comparison: Novartis AG vs Bausch Health Companies Inc.
Revenue Insights: Gilead Sciences, Inc. and Alnylam Pharmaceuticals, Inc. Performance Compared
Who Generates More Revenue? Gilead Sciences, Inc. or Bausch Health Companies Inc.
Alnylam Pharmaceuticals, Inc. vs Exelixis, Inc.: Examining Key Revenue Metrics
Alnylam Pharmaceuticals, Inc. vs Halozyme Therapeutics, Inc.: Examining Key Revenue Metrics
Breaking Down Revenue Trends: Alnylam Pharmaceuticals, Inc. vs ImmunityBio, Inc.
Alnylam Pharmaceuticals, Inc. and Mesoblast Limited: A Comprehensive Revenue Analysis
Revenue Showdown: Biogen Inc. vs Bausch Health Companies Inc.
Breaking Down Revenue Trends: BeiGene, Ltd. vs Bausch Health Companies Inc.
Cytokinetics, Incorporated and Bausch Health Companies Inc.: A Comprehensive Revenue Analysis
Revenue Insights: ADMA Biologics, Inc. and Bausch Health Companies Inc. Performance Compared
Revenue Insights: Bausch Health Companies Inc. and Galapagos NV Performance Compared